|  |
June 2005 Stock Report
|
|
6/30/05 Close
|
% of 52wk High
|
% change since 6/30/04
|
Market Cap
($M)
|
Liquidity, Pro forma ($M)
|
ST< Debt ($M)
|
Company Valuation ($M)
|
Valuation/
Employee ($M)
|
Burn Rate, annualized ($M)
|
Survival Index (Yrs)
|
IPO Date
|
Cash/cash from IPO/share
|
Price/Share At IPO
|
IPO Post-Money Valuation ($M)
|
| HUMAN GENOME SCIENCES |
$11.58 |
84% |
0% |
$1,513 |
$582 |
$505 |
$1,436 |
$1.3 |
-$267 |
2.2 |
Dec-93 |
3.9 |
$3.00 |
$176 |
| INCYTE CORP. |
$7.15 |
64% |
-6% |
$594 |
$429 |
$379 |
$544 |
$1.2 |
-$104 |
4.1 |
Nov-93 |
3.8 |
$1.88 |
$47 |
| MILLENNIUM PHARMACEUTICALS |
$9.27 |
66% |
-33% |
$2,851 |
$497 |
$193 |
$2,548 |
$1.7 |
-$379 |
1.3 |
May-96 |
3.1 |
$3.00 |
$273 |
| MYRIAD GENETICS |
$15.65 |
60% |
5% |
$482 |
$74 |
$0 |
$408 |
$0.8 |
-$40 |
1.8 |
Oct-95 |
1.7 |
$9.00 |
$163 |
| OSCIENT PHARMACEUTICALS |
$2.65 |
53% |
-48% |
$203 |
$110 |
$0 |
$93 |
$1.5 |
-$129 |
0.9 |
Feb-82 |
0.2 |
$11.00 |
$90 |
| 1st Generation Genomics Average |
|
65% |
-17% |
$1,129 |
$338 |
|
$1,006 |
$1.3 |
-$184 |
2.1 |
|
2.5 |
|
|
| 1st Generation Genomics Median |
|
64% |
-6% |
$594 |
$429 |
|
$544 |
$1.3 |
-$129 |
1.8 |
|
3.1 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
6/30/05 Close
|
% of 52wk High
|
% change since 6/30/04
|
Market Cap
($M)
|
Liquidity, Pro forma ($M)
|
ST< Debt ($M)
|
Company Valuation ($M)
|
Valuation/
Employee ($M)
|
Burn Rate, annualized ($M)
|
Survival Index (Yrs)
|
IPO Date
|
Cash/cash from IPO/share
|
Price/Share At IPO
|
IPO Post-Money Valuation ($M)
|
| AFFYMETRIX |
$53.92 |
98% |
65% |
$3,403 |
$260 |
$120 |
$3,263 |
$3.7 |
na |
na |
Jun-96 |
7.2 |
$7.50 |
$287 |
| CALIPER LIFE SCIENCES |
$5.60 |
67% |
20% |
$171 |
$44 |
$1 |
$128 |
$0.3 |
-$28 |
1.6 |
Dec-99 |
0.4 |
$16.00 |
$333 |
| CEPHEID |
$7.34 |
64% |
-36% |
$312 |
$54 |
$7 |
$265 |
$1.5 |
-$12 |
4.5 |
Jun-00 |
1.2 |
$6.00 |
$158 |
| CIPHERGEN BIOSYSTEMS |
$1.91 |
32% |
-74% |
$56 |
$34 |
$29 |
$52 |
$0.2 |
na |
na |
Sep-00 |
0.1 |
$16.00 |
$417 |
| COMBIMATRIX CORP. |
$2.34 |
48% |
-46% |
$73 |
$17 |
$0 |
$56 |
$1.0 |
-$14 |
1.2 |
na |
na |
na |
na |
| COMPUGEN LTD |
$3.20 |
49% |
-32% |
$89 |
$16 |
$0 |
$73 |
$0.4 |
-$15 |
1.1 |
Sep-00 |
0.3 |
$10.00 |
$0 |
| ILLUMINA |
$12.07 |
93% |
91% |
$466 |
$64 |
$0 |
$402 |
$11.2 |
na |
na |
Jul-00 |
0.8 |
$16.00 |
$515 |
| NANOGEN |
$3.84 |
47% |
-43% |
$183 |
$30 |
$1 |
$155 |
$1.1 |
-$45 |
0.7 |
Apr-98 |
0.3 |
$11.00 |
$197 |
| ORCHID CELLMARK |
$10.81 |
75% |
24% |
$264 |
$31 |
$1 |
$234 |
$0.6 |
na |
na |
May-00 |
1.4 |
$8.00 |
$263 |
| SEQUENOM |
$1.16 |
64% |
-21% |
$47 |
$21 |
$7 |
$33 |
$0.2 |
-$26 |
0.8 |
Feb-00 |
0.0 |
$26.00 |
$609 |
| TRANSGENOMIC |
$0.68 |
41% |
-48% |
$23 |
($6) |
$8 |
$37 |
$0.2 |
-$34 |
(0.2) |
Jul-00 |
0.0 |
$15.00 |
$317 |
| Genomic Supply Average |
|
62% |
-9% |
$463 |
$51 |
|
$427 |
$1.8 |
-$25 |
1.4 |
|
1.2 |
|
|
| Genomic Supply Median |
|
64% |
-32% |
$171 |
$31 |
|
$128 |
$0.6 |
-$26 |
1.1 |
|
0.3 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
6/30/05 Close
|
% of 52wk High
|
% change since 6/30/04
|
Market Cap
($M)
|
Liquidity, Pro forma ($M)
|
ST< Debt ($M)
|
Company Valuation ($M)
|
Valuation/
Employee ($M)
|
Burn Rate, annualized ($M)
|
Survival Index (Yrs)
|
IPO Date
|
Cash/cash from IPO/share
|
Price/Share At IPO
|
IPO Post-Money Valuation ($M)
|
| ARENA PHARMACEUTICALS |
$6.82 |
91% |
25% |
$240 |
$153 |
$0 |
$87 |
$0.3 |
-$70 |
2.2 |
Jul-00 |
0.4 |
$18.00 |
$394 |
| CELERA GENOMICS GROUP |
$10.97 |
74% |
-5% |
$809 |
na |
na |
na |
na |
-$78 |
na |
Feb-00 |
0.0 |
$225.00 |
na |
| CURAGEN CORP. |
$5.14 |
65% |
-14% |
$261 |
$282 |
$240 |
$219 |
$0.7 |
-$91 |
3.1 |
Mar-98 |
0.9 |
$5.75 |
$143 |
| DECODE GENETICS |
$9.39 |
94% |
10% |
$512 |
$183 |
$161 |
$491 |
$1.2 |
-$78 |
2.4 |
Jul-00 |
0.5 |
$18.00 |
$818 |
| EXELIXIS |
$7.43 |
74% |
-26% |
$567 |
$77 |
$143 |
$633 |
$1.1 |
-$208 |
0.4 |
Apr-00 |
0.6 |
$13.00 |
$520 |
| GENAISSANCE PHARMACEUTICALS |
$1.12 |
26% |
-73% |
$40 |
$3 |
$7 |
$43 |
$0.4 |
-$16 |
0.2 |
Aug-00 |
0.1 |
$13.00 |
$288 |
| GENE LOGIC |
$3.31 |
79% |
-18% |
$105 |
$98 |
$1 |
$8 |
$0.0 |
-$16 |
6.1 |
Nov-97 |
0.4 |
$8.00 |
$109 |
| ICORIA INC. |
$0.15 |
16% |
-81% |
$6 |
$10 |
$6 |
$2 |
$0.0 |
-$12 |
0.8 |
May-00 |
0.0 |
$7.00 |
$177 |
| LARGE SCALE BIOLOGY CORP. |
$0.97 |
61% |
-30% |
$31 |
($4) |
$4 |
$38 |
$0.5 |
-$20 |
(0.2) |
Aug-00 |
0.1 |
$17.00 |
$388 |
| LEXICON GENETICS |
$4.94 |
62% |
-37% |
$314 |
$73 |
$37 |
$278 |
$0.4 |
-$2 |
36.7 |
Apr-00 |
0.2 |
$22.00 |
$1,037 |
| MAXYGEN |
$6.86 |
54% |
-35% |
$245 |
$171 |
$0 |
$74 |
$0.3 |
-$62 |
2.8 |
Dec-99 |
0.4 |
$16.00 |
$465 |
| RIGEL PHARMACEUTICALS |
$19.92 |
69% |
40% |
$396 |
$58 |
$3 |
$340 |
$2.7 |
-$59 |
1.0 |
Nov-00 |
2.8 |
$7.00 |
$230 |
| SANGAMO BIOSCIENCES |
$3.57 |
55% |
-40% |
$91 |
$27 |
$0 |
$64 |
$1.1 |
-$12 |
2.3 |
Apr-00 |
0.2 |
$15.00 |
$312 |
| ZYMOGENETICS |
$17.60 |
71% |
-7% |
$1,017 |
$281 |
$66 |
$803 |
$2.2 |
-$94 |
3.0 |
Feb-01 |
1.5 |
$12.00 |
$547 |
| Genomic Targets Average |
|
64% |
-21% |
$331 |
$109 |
|
$237 |
$0.8 |
-$58 |
4.7 |
|
0.6 |
|
|
| Genomic Targets Median |
|
67% |
-22% |
$253 |
$77 |
|
$87 |
$0.5 |
-$60 |
2.3 |
|
0.4 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
6/30/05 Close
|
% of 52wk High
|
% change since 6/30/04
|
Market Cap
($M)
|
Liquidity, Pro forma ($M)
|
ST< Debt ($M)
|
Company Valuation ($M)
|
Valuation/
Employee ($M)
|
Burn Rate, annualized ($M)
|
Survival Index (Yrs)
|
IPO Date
|
Cash/cash from IPO/share
|
Price/Share At IPO
|
IPO Post-Money Valuation ($M)
|
| ALEXION PHARMACEUTICALS |
$23.04 |
85% |
24% |
$648 |
$207 |
$150 |
$591 |
$3.1 |
-$98 |
2.1 |
Feb-96 |
2.8 |
$8.25 |
$62 |
| ATHEROGENICS |
$15.98 |
38% |
-16% |
$602 |
$225 |
$300 |
$677 |
$7.0 |
-$70 |
3.2 |
Aug-00 |
2.0 |
$8.00 |
$184 |
| CONNETICS CORP. |
$17.64 |
58% |
-13% |
$614 |
$243 |
$290 |
$660 |
$3.1 |
na |
na |
Feb-96 |
1.6 |
$11.00 |
$81 |
| CORTECH |
$3.26 |
86% |
3% |
$12 |
$11 |
$0 |
$0 |
$0.3 |
na |
na |
Nov-92 |
0.1 |
$40.00 |
$116 |
| CYPRESS BIOSCIENCE |
$13.20 |
92% |
-4% |
$401 |
$112 |
$0 |
$290 |
$19.3 |
na |
na |
Dec-83 |
0.2 |
$80.00 |
$33 |
| ICOS CORP. |
$21.17 |
70% |
-29% |
$1,352 |
$168 |
$279 |
$1,462 |
$2.2 |
-$134 |
1.3 |
Jun-91 |
2.6 |
$8.00 |
$172 |
| INKINE PHARMACEUTICAL CO. |
$3.19 |
53% |
-18% |
$157 |
$11 |
$0 |
$145 |
$2.6 |
na |
na |
na |
na |
na |
na |
| LA JOLLA PHARMACEUTICAL |
$0.80 |
21% |
-67% |
$59 |
$20 |
$1 |
$41 |
$0.3 |
-$44 |
0.4 |
Jun-94 |
0.2 |
$5.00 |
$43 |
| PROTEIN DESIGN LABS |
$20.21 |
93% |
6% |
$2,143 |
$184 |
$508 |
$2,466 |
$4.5 |
-$58 |
3.2 |
Jan-92 |
2.7 |
$7.50 |
$191 |
| TANOX |
$11.72 |
61% |
-39% |
$525 |
$148 |
$5 |
$382 |
$3.2 |
-$15 |
9.7 |
Apr-00 |
0.4 |
$28.50 |
$1,193 |
| Autoimmune Average |
|
66% |
-15% |
$651 |
$133 |
|
$672 |
$4.6 |
-$70 |
3.3 |
|
1.4 |
|
|
| Autoimmune Median |
|
66% |
-14% |
$564 |
$158 |
|
$487 |
$3.1 |
-$64 |
2.6 |
|
1.6 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
6/30/05 Close
|
% of 52wk High
|
% change since 6/30/04
|
Market Cap
($M)
|
Liquidity, Pro forma ($M)
|
ST< Debt ($M)
|
Company Valuation ($M)
|
Valuation/
Employee ($M)
|
Burn Rate, annualized ($M)
|
Survival Index (Yrs)
|
IPO Date
|
Cash/cash from IPO/share
|
Price/Share At IPO
|
IPO Post-Money Valuation ($M)
|
| ALLOS THERAPEUTICS |
$2.18 |
72% |
-3% |
$68 |
$53 |
$0 |
$15 |
$0.3 |
-$20 |
2.6 |
Mar-00 |
0.1 |
$18.00 |
$604 |
| ANTIGENICS |
$5.41 |
48% |
-37% |
$246 |
$102 |
$59 |
$203 |
$0.9 |
-$68 |
1.5 |
Feb-00 |
0.3 |
$18.00 |
$429 |
| APHTON CORP. |
$0.74 |
17% |
-82% |
$44 |
$37 |
$12 |
$20 |
$0.4 |
-$29 |
1.3 |
na |
na |
na |
na |
| ARIAD PHARMACEUTICALS |
$6.66 |
83% |
-11% |
$352 |
$53 |
$9 |
$309 |
$5.9 |
-$43 |
1.2 |
May-94 |
0.8 |
$8.00 |
$124 |
| AVI BIOPHARMA |
$2.32 |
55% |
-3% |
$102 |
$32 |
$0 |
$70 |
$0.7 |
-$20 |
1.6 |
Jun-97 |
0.3 |
$9.00 |
$103 |
| BIOMIRA |
$1.72 |
41% |
33% |
$135 |
$25 |
$0 |
$110 |
$0.7 |
-$15 |
1.6 |
Jun-87 |
0.4 |
$4.40 |
$43 |
| BOSTON LIFE SCIENCES |
$2.10 |
42% |
-59% |
$22 |
$3 |
$0 |
$19 |
$1.6 |
-$10 |
0.3 |
na |
na |
na |
na |
| CANCERVAX |
$2.85 |
25% |
-63% |
$79 |
$64 |
$10 |
$26 |
$0.2 |
-$57 |
1.1 |
Oct-03 |
0.2 |
$12.00 |
$308 |
| CELGENE CORP. |
$40.70 |
94% |
-29% |
$6,790 |
$782 |
$400 |
$6,408 |
$9.4 |
na |
na |
Jul-87 |
11.1 |
$3.66 |
$55 |
| CELL THERAPEUTICS |
$2.71 |
25% |
-63% |
$175 |
$40 |
$222 |
$356 |
$1.0 |
-$174 |
0.2 |
Mar-97 |
0.3 |
$10.00 |
$166 |
| CORIXA CORP. |
$4.38 |
82% |
-6% |
$261 |
$57 |
$127 |
$331 |
$1.0 |
-$99 |
0.6 |
Oct-97 |
0.3 |
$13.00 |
$152 |
| CYTOGEN CORP. |
$5.23 |
31% |
-67% |
$81 |
$21 |
$2 |
$62 |
$1.0 |
-$25 |
0.8 |
Jun-86 |
0.4 |
$13.00 |
$148 |
| CYTOKINETICS |
$6.94 |
46% |
-53% |
$198 |
$92 |
$10 |
$116 |
$0.7 |
-$47 |
2.0 |
Apr-04 |
0.5 |
$13.00 |
$371 |
| DENDREON CORP. |
$5.23 |
39% |
-57% |
$310 |
$153 |
$5 |
$162 |
$1.1 |
-$88 |
1.7 |
Jun-00 |
0.5 |
$10.00 |
$210 |
| DUSA PHARMACEUTICALS |
$9.30 |
57% |
-2% |
$157 |
$40 |
$0 |
$117 |
$2.3 |
-$16 |
2.5 |
Jan-92 |
1.6 |
$6.00 |
$30 |
| ENTREMED |
$2.31 |
48% |
15% |
$115 |
$41 |
$0 |
$74 |
$1.7 |
-$12 |
3.3 |
Jun-96 |
0.2 |
$15.00 |
$182 |
| EXEGENICS |
$0.36 |
42% |
-51% |
$6 |
$8 |
$0 |
($2) |
($0.3) |
-$2 |
3.7 |
na |
na |
na |
na |
| GENAERA CORP. |
$1.70 |
39% |
-60% |
$97 |
$21 |
$0 |
$76 |
$3.3 |
-$20 |
1.1 |
Dec-91 |
0.2 |
$9.00 |
$62 |
| GENITOPE |
$12.84 |
73% |
30% |
$363 |
$104 |
$0 |
$259 |
$2.8 |
-$27 |
3.9 |
Oct-03 |
1.4 |
$9.00 |
$145 |
| GENTA |
$1.18 |
37% |
-53% |
$113 |
$33 |
$4 |
$84 |
$0.5 |
na |
na |
Dec-91 |
0.0 |
$100.00 |
$123 |
| GERON CORP. |
$7.74 |
79% |
-4% |
$429 |
$118 |
$2 |
$313 |
$5.9 |
-$38 |
3.1 |
Jul-96 |
1.0 |
$8.00 |
$77 |
| GTX |
$9.94 |
67% |
-5% |
$245 |
$51 |
$0 |
$194 |
$4.6 |
-$28 |
1.8 |
Feb-04 |
0.7 |
$14.50 |
$358 |
| IMCLONE SYSTEMS |
$30.97 |
35% |
-64% |
$2,590 |
$842 |
$600 |
$2,348 |
$5.6 |
-$53 |
15.9 |
Nov-91 |
4.4 |
$7.00 |
$107 |
| IMMUNOGEN |
$5.79 |
62% |
-5% |
$237 |
$90 |
$0 |
$147 |
$1.3 |
-$9 |
10.2 |
Nov-89 |
0.6 |
$10.00 |
$60 |
| IMMUNOMEDICS |
$1.71 |
34% |
-65% |
$92 |
$8 |
$14 |
$99 |
$0.9 |
-$26 |
0.3 |
Oct-83 |
1.4 |
$1.25 |
$25 |
| MAXIM PHARMACEUTICALS |
$1.30 |
14% |
-87% |
$37 |
$22 |
$1 |
$16 |
$0.2 |
-$38 |
0.6 |
Jul-96 |
0.2 |
$7.50 |
$50 |
| MEDAREX |
$8.30 |
72% |
14% |
$919 |
$351 |
$264 |
$832 |
$2.0 |
-$228 |
1.5 |
Jun-91 |
2.8 |
$3.00 |
$31 |
| NEOPHARM |
$9.99 |
74% |
-3% |
$235 |
$41 |
$0 |
$195 |
$1.9 |
-$58 |
0.7 |
Jan-96 |
3.1 |
$3.18 |
$28 |
| NEORX CORP. |
$0.60 |
21% |
-76% |
$21 |
$12 |
$4 |
$13 |
$0.3 |
-$18 |
0.7 |
Aug-88 |
0.0 |
$28.00 |
$102 |
| ONYX PHARMACEUTICALS |
$23.82 |
53% |
-44% |
$841 |
$182 |
$0 |
$658 |
$41.1 |
-$56 |
3.2 |
May-96 |
2.0 |
$12.00 |
$105 |
| OSI PHARMACEUTICALS |
$40.87 |
55% |
-42% |
$2,095 |
$609 |
$150 |
$1,637 |
$3.4 |
-$194 |
3.1 |
Apr-86 |
6.8 |
$6.00 |
$53 |
| OXIGENE |
$4.54 |
63% |
-28% |
$91 |
$40 |
$0 |
$51 |
$4.6 |
-$9 |
4.6 |
Oct-93 |
0.8 |
$6.00 |
$28 |
| PHARMION |
$23.21 |
40% |
-53% |
$739 |
$250 |
$0 |
$489 |
$8.3 |
na |
na |
Nov-03 |
1.7 |
$14.00 |
$358 |
| PRAECIS PHARMACEUTICALS |
$0.52 |
13% |
-86% |
$27 |
$56 |
$32 |
$3 |
$0.0 |
-$54 |
1.0 |
Apr-00 |
0.1 |
$10.00 |
$400 |
| PROGENICS PHARMACEUTICALS |
$20.86 |
85% |
24% |
$408 |
$13 |
$0 |
$395 |
$3.4 |
-$42 |
0.3 |
Nov-97 |
2.6 |
$8.00 |
$70 |
| QLT |
$10.42 |
51% |
-48% |
$978 |
$425 |
$173 |
$725 |
$2.2 |
na |
na |
Sep-86 |
9.6 |
$1.08 |
$22 |
| SCICLONE PHARMACEUTICALS |
$4.49 |
87% |
-11% |
$201 |
$46 |
$6 |
$161 |
$1.5 |
-$10 |
4.8 |
Mar-92 |
0.6 |
$7.45 |
$63 |
| SEATTLE GENETICS |
$5.36 |
68% |
-24% |
$226 |
$34 |
$0 |
$192 |
$1.8 |
-$42 |
0.8 |
Mar-01 |
0.8 |
$7.00 |
$207 |
| SPECTRUM PHARMACEUTICALS |
$4.20 |
55% |
-33% |
$64 |
$34 |
$0 |
$31 |
$1.9 |
-$16 |
2.1 |
na |
na |
na |
na |
| SUPERGEN |
$4.94 |
61% |
-23% |
$253 |
$63 |
$0 |
$190 |
$1.6 |
na |
na |
Mar-96 |
0.8 |
$6.00 |
$21 |
| TAPESTRY PHARMACEUTICALS |
$0.46 |
25% |
-74% |
$15 |
$19 |
$3 |
$0 |
$0.0 |
-$32 |
0.6 |
Apr-94 |
0.1 |
$5.00 |
$41 |
| VERNALIS |
$2.13 |
44% |
-6% |
$11 |
$73 |
$116 |
$53 |
$0.6 |
-$48 |
1.5 |
May-96 |
0.3 |
$7.20 |
$178 |
| XCYTE THERAPIES |
$0.72 |
15% |
-84% |
$14 |
$34 |
$2 |
($18) |
($0.3) |
-$27 |
1.3 |
Mar-04 |
0.1 |
$8.00 |
$157 |
| XENOVA PLC |
$0.74 |
36% |
-64% |
$32 |
$26 |
$0 |
$6 |
$0.0 |
-$12 |
2.3 |
Jul-94 |
0.0 |
$16.00 |
$90 |
| Cancer Average |
|
50% |
-34% |
$466 |
$118 |
|
$399 |
$2.9 |
-$46 |
2.3 |
|
1.5 |
|
|
| Cancer Median |
|
48% |
-39% |
$166 |
$43 |
|
$116 |
$1.4 |
-$29 |
1.5 |
|
0.6 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
6/30/05 Close
|
% of 52wk High
|
% change since 6/30/04
|
Market Cap
($M)
|
Liquidity, Pro forma ($M)
|
ST< Debt ($M)
|
Company Valuation ($M)
|
Valuation/
Employee ($M)
|
Burn Rate, annualized ($M)
|
Survival Index (Yrs)
|
IPO Date
|
Cash/cash from IPO/share
|
Price/Share At IPO
|
IPO Post-Money Valuation ($M)
|
| CORGENTECH |
$2.60 |
13% |
-84% |
$73 |
$93 |
$1 |
($20) |
($0.3) |
-$50 |
1.9 |
Feb-04 |
0.2 |
$16.00 |
$450 |
| CV THERAPEUTICS |
$22.42 |
91% |
34% |
$808 |
$359 |
$330 |
$779 |
$3.0 |
-$215 |
1.7 |
Nov-96 |
2.8 |
$8.00 |
$48 |
| ENCYSIVE PHARMACEUTICALS |
$10.81 |
87% |
27% |
$628 |
$169 |
$132 |
$591 |
$6.4 |
-$59 |
2.9 |
Dec-93 |
1.6 |
$6.75 |
$88 |
| MEDICINES COMPANY |
$23.33 |
72% |
-24% |
$1,153 |
$156 |
$0 |
$997 |
$5.2 |
na |
na |
Sep-00 |
1.5 |
$16.00 |
$506 |
| MYOGEN |
$6.99 |
72% |
-10% |
$250 |
$89 |
$2 |
$163 |
$2.9 |
-$52 |
1.7 |
Oct-03 |
0.5 |
$14.00 |
$358 |
| NITROMED |
$19.45 |
69% |
221% |
$589 |
$118 |
$0 |
$471 |
$11.5 |
-$43 |
2.7 |
Nov-03 |
1.8 |
$11.00 |
$264 |
| NUVELO |
$7.73 |
69% |
-20% |
$325 |
$97 |
$15 |
$243 |
$3.9 |
-$52 |
1.9 |
Sep-97 |
0.6 |
$14.00 |
$175 |
| QUESTCOR PHARMACEUTICALS |
$0.64 |
75% |
-25% |
$34 |
$9 |
$6 |
$31 |
$0.6 |
na |
na |
na |
na |
na |
na |
| Cardiovascular Average |
|
68% |
15% |
$482 |
$136 |
|
$407 |
$4.1 |
-$78 |
2.1 |
|
1.3 |
|
|
| Cardiovascular Median |
|
72% |
-15% |
$457 |
$107 |
|
$357 |
$3.4 |
-$52 |
1.9 |
|
1.5 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
6/30/05 Close
|
% of 52wk High
|
% change since 6/30/04
|
Market Cap
($M)
|
Liquidity, Pro forma ($M)
|
ST< Debt ($M)
|
Company Valuation ($M)
|
Valuation/
Employee ($M)
|
Burn Rate, annualized ($M)
|
Survival Index (Yrs)
|
IPO Date
|
Cash/cash from IPO/share
|
Price/Share At IPO
|
IPO Post-Money Valuation ($M)
|
| ACCELRYS |
$4.95 |
49% |
-50% |
$129 |
$58 |
$3 |
$74 |
$0.1 |
-$19 |
3.1 |
Dec-95 |
0.3 |
$16.00 |
$158 |
| ALBANY MOLECULAR RESEARCH |
$14.00 |
96% |
8% |
$452 |
$148 |
$52 |
$356 |
$0.4 |
na |
na |
Feb-99 |
1.4 |
$10.00 |
$280 |
| ARGONAUT TECHNOLOGIES |
$0.99 |
74% |
-26% |
$21 |
$7 |
$0 |
$13 |
$0.1 |
-$14 |
0.5 |
Jul-00 |
0.1 |
$15.00 |
$253 |
| ARQULE |
$6.48 |
94% |
23% |
$226 |
$79 |
$0 |
$147 |
$0.6 |
na |
na |
Oct-96 |
0.5 |
$12.00 |
$114 |
| ARRAY BIOPHARMA |
$6.30 |
63% |
-21% |
$242 |
$87 |
$0 |
$155 |
$0.6 |
-$20 |
4.4 |
Nov-01 |
0.8 |
$7.50 |
$168 |
| BIOCRYST PHARMACEUTICALS |
$5.08 |
67% |
-26% |
$133 |
$37 |
$0 |
$96 |
$2.1 |
-$21 |
1.8 |
Mar-94 |
0.8 |
$6.50 |
$47 |
| DISCOVERY PARTNERS INTL |
$2.86 |
48% |
-44% |
$75 |
$87 |
$0 |
($12) |
($0.1) |
na |
na |
Jul-00 |
0.2 |
$18.00 |
$428 |
| KOSAN BIOSCIENCES |
$5.28 |
65% |
-33% |
$154 |
$57 |
$4 |
$102 |
$0.8 |
-$28 |
2.1 |
Oct-00 |
0.4 |
$14.00 |
$341 |
| SYMYX TECHNOLOGIES |
$27.98 |
87% |
16% |
$912 |
$152 |
$0 |
$760 |
$3.2 |
na |
na |
Nov-99 |
2.0 |
$14.00 |
$398 |
| VERTEX PHARMACEUTICALS |
$16.85 |
99% |
55% |
$1,370 |
$296 |
$335 |
$1,408 |
$2.0 |
-$171 |
1.7 |
Jul-91 |
3.7 |
$4.50 |
$85 |
| Chemistry Average |
|
74% |
-10% |
$371 |
$101 |
|
$310 |
$1.0 |
-$45 |
2.3 |
|
1.0 |
|
|
| Chemistry Median |
|
71% |
-23% |
$190 |
$83 |
|
$124 |
$0.6 |
-$20 |
1.9 |
|
0.7 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
6/30/05 Close
|
% of 52wk High
|
% change since 6/30/04
|
Market Cap
($M)
|
Liquidity, Pro forma ($M)
|
ST< Debt ($M)
|
Company Valuation ($M)
|
Valuation/
Employee ($M)
|
Burn Rate, annualized ($M)
|
Survival Index (Yrs)
|
IPO Date
|
Cash/cash from IPO/share
|
Price/Share At IPO
|
IPO Post-Money Valuation ($M)
|
| ACADIA PHARMACEUTICALS |
$8.40 |
88% |
35% |
$196 |
$43 |
$2 |
$155 |
$1.5 |
-$29 |
1.5 |
May-04 |
1.2 |
$7.00 |
$163 |
| ADOLOR CORP. |
$9.25 |
55% |
-27% |
$362 |
$138 |
$0 |
$223 |
$1.8 |
-$46 |
3.0 |
Nov-00 |
0.6 |
$15.00 |
$407 |
| CEPHALON |
$39.80 |
72% |
-26% |
$2,310 |
$912 |
$1,288 |
$2,687 |
$1.6 |
na |
na |
Apr-91 |
2.2 |
$18.00 |
$155 |
| CORCEPT THERAPEUTICS |
$5.76 |
64% |
-25% |
$131 |
$29 |
$0 |
$102 |
$14.5 |
-$16 |
1.8 |
Apr-04 |
0.5 |
$12.00 |
$272 |
| DOV PHARMACEUTICAL |
$18.66 |
94% |
34% |
$425 |
$101 |
$80 |
$403 |
$11.2 |
-$48 |
2.1 |
Apr-02 |
1.4 |
$13.00 |
$188 |
| GUILFORD PHARMACEUTICALS |
$2.27 |
39% |
-52% |
$106 |
$66 |
$73 |
$113 |
$0.4 |
-$136 |
0.5 |
Jun-94 |
0.4 |
$5.33 |
$30 |
| INDEVUS PHARMACEUTICALS |
$2.56 |
32% |
-58% |
$120 |
$99 |
$72 |
$93 |
$3.4 |
-$84 |
1.2 |
Mar-90 |
1.3 |
$2.00 |
$31 |
| MEMORY PHARMACEUTICALS |
$1.85 |
19% |
-80% |
$38 |
$25 |
$4 |
$17 |
$0.2 |
-$27 |
0.9 |
Apr-04 |
0.3 |
$7.00 |
$146 |
| NEUROBIOLOGICAL TECHNOLOGIES |
$3.02 |
60% |
-19% |
$82 |
$2 |
$0 |
$80 |
$7.2 |
-$11 |
0.2 |
Feb-94 |
0.4 |
$8.00 |
$30 |
| NEUROCRINE BIOSCIENCES |
$42.06 |
77% |
-19% |
$1,541 |
$256 |
$65 |
$1,349 |
$4.3 |
-$82 |
3.1 |
May-96 |
4.0 |
$10.50 |
$172 |
| NEW RIVER PHARMACEUTICALS |
$30.02 |
89% |
na |
$537 |
$66 |
$0 |
$471 |
$21.4 |
-$5 |
13.8 |
Aug-04 |
3.8 |
$8.00 |
$142 |
| NYMOX PHARMACEUTICAL CORP. |
$2.45 |
64% |
-35% |
$63 |
($1) |
$1 |
$64 |
$3.0 |
-$3 |
(0.2) |
na |
na |
na |
na |
| PAIN THERAPEUTICS |
$6.75 |
80% |
-16% |
$295 |
($9) |
$0 |
$304 |
$10.1 |
-$37 |
(0.2) |
Jul-00 |
0.6 |
$12.00 |
$319 |
| PHARMOS CORP. |
$2.45 |
12% |
-88% |
$47 |
$51 |
$0 |
($4) |
($0.1) |
-$19 |
2.6 |
Jul-83 |
0.0 |
$100.00 |
$16 |
| RENOVIS |
$15.27 |
79% |
67% |
$377 |
$69 |
$4 |
$313 |
$4.3 |
-$42 |
1.6 |
Feb-04 |
1.3 |
$12.00 |
$297 |
| TITAN PHARMACEUTICALS |
$1.83 |
54% |
-32% |
$59 |
$24 |
$0 |
$35 |
$0.6 |
-$31 |
0.8 |
Jan-96 |
0.4 |
$5.00 |
$66 |
| CNS Average |
|
61% |
-23% |
$418 |
$117 |
|
$400 |
$5.4 |
-$41 |
2.2 |
|
1.2 |
|
|
| CNS Median |
|
64% |
-26% |
$163 |
$58 |
|
$134 |
$3.2 |
-$31 |
1.5 |
|
0.6 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
6/30/05 Close
|
% of 52wk High
|
% change since 6/30/04
|
Market Cap
($M)
|
Liquidity, Pro forma ($M)
|
ST< Debt ($M)
|
Company Valuation ($M)
|
Valuation/
Employee ($M)
|
Burn Rate, annualized ($M)
|
Survival Index (Yrs)
|
IPO Date
|
Cash/cash from IPO/share
|
Price/Share At IPO
|
IPO Post-Money Valuation ($M)
|
| ABGENIX |
$8.58 |
73% |
-27% |
$770 |
$368 |
$464 |
$865 |
$2.1 |
-$172 |
2.1 |
Jul-98 |
4.3 |
$2.00 |
$86 |
| ACUSPHERE |
$4.77 |
57% |
-25% |
$85 |
$76 |
$12 |
$21 |
$0.4 |
-$25 |
3.0 |
Oct-03 |
0.3 |
$14.00 |
$200 |
| AEROGEN |
$0.40 |
12% |
-87% |
$3 |
$12 |
$0 |
($9) |
($0.1) |
-$9 |
1.4 |
Nov-00 |
0.0 |
$12.00 |
$233 |
| ALKERMES |
$13.22 |
85% |
-3% |
$1,195 |
$196 |
$278 |
$1,277 |
$2.9 |
-$36 |
5.5 |
Jul-91 |
2.6 |
$5.00 |
$70 |
| ANDRX CORP. |
$20.31 |
72% |
-27% |
$1,486 |
$348 |
$0 |
$1,138 |
$0.5 |
na |
na |
Jun-96 |
6.8 |
$3.00 |
$155 |
| ARADIGM CORP. |
$1.06 |
49% |
18% |
$77 |
$48 |
$0 |
$29 |
$0.1 |
-$27 |
1.8 |
Jun-96 |
0.1 |
$11.00 |
$114 |
| BIODELIVERY SCIENCES INTL |
$3.01 |
70% |
0% |
$22 |
$2 |
$2 |
$22 |
$1.2 |
na |
na |
na |
na |
na |
na |
| DEPOMED |
$4.37 |
74% |
-12% |
$174 |
$26 |
$11 |
$158 |
$2.1 |
-$27 |
1.0 |
Nov-97 |
0.7 |
$6.10 |
$33 |
| DOR BIOPHARMA |
$0.32 |
40% |
-42% |
$16 |
$3 |
$0 |
$13 |
$3.3 |
-$6 |
0.6 |
na |
na |
na |
na |
| DURECT CORP. |
$5.09 |
97% |
47% |
$264 |
$33 |
$61 |
$293 |
$2.7 |
-$28 |
1.2 |
Sep-00 |
0.4 |
$12.00 |
$557 |
| EMISPHERE TECHNOLOGIES |
$4.02 |
67% |
-2% |
$94 |
$19 |
$24 |
$98 |
$0.8 |
-$35 |
0.5 |
Feb-89 |
0.8 |
$5.00 |
$15 |
| ENZON PHARMACEUTICALS |
$6.48 |
39% |
-49% |
$284 |
$161 |
$400 |
$523 |
$1.6 |
-$2 |
80.5 |
Feb-84 |
4.3 |
$1.50 |
$12 |
| FLAMEL TECHNOLOGIES SA |
$18.11 |
67% |
-26% |
$394 |
$105 |
$2 |
$290 |
$1.9 |
na |
na |
na |
na |
na |
na |
| GENEREX BIOTECHNOLOGY CORP. |
$0.63 |
40% |
-57% |
$25 |
($6) |
$5 |
$35 |
$1.4 |
-$27 |
(0.2) |
na |
na |
na |
na |
| INOVIO BIOMEDICALCORP |
$3.11 |
60% |
-40% |
$59 |
$5 |
$0 |
$54 |
$2.7 |
-$28 |
0.2 |
na |
na |
na |
na |
| KOS PHARMACEUTICALS |
$65.50 |
95% |
99% |
$2,647 |
$334 |
$19 |
$2,332 |
$2.6 |
na |
na |
Mar-97 |
4.4 |
$15.00 |
$233 |
| MACROCHEM CORP. |
$0.24 |
16% |
-83% |
$10 |
$3 |
$0 |
$7 |
$0.4 |
-$8 |
0.4 |
Feb-85 |
0.1 |
$3.00 |
$13 |
| MEDICIS PHARMACEUTICAL CORP. |
$31.73 |
77% |
-21% |
$1,722 |
$593 |
$481 |
$1,610 |
$5.2 |
na |
na |
na |
na |
na |
na |
| NASTECH PHARMACEUTICAL |
$14.23 |
86% |
40% |
$256 |
$52 |
$3 |
$207 |
$2.5 |
-$24 |
2.2 |
na |
na |
na |
na |
| NEKTAR THERAPEUTICS |
$16.83 |
82% |
-16% |
$1,430 |
$393 |
$196 |
$1,234 |
$1.8 |
-$77 |
5.1 |
May-94 |
4.5 |
$3.75 |
$65 |
| NOVAVAX |
$1.32 |
23% |
-76% |
$53 |
$0 |
$37 |
$89 |
$0.8 |
-$41 |
0.0 |
na |
na |
na |
na |
| NOVEN PHARMACEUTICALS |
$17.48 |
71% |
-21% |
$412 |
$94 |
$0 |
$319 |
$1.0 |
na |
na |
May-88 |
31.8 |
$0.55 |
$5 |
| SEPRACOR |
$60.01 |
90% |
13% |
$6,287 |
$653 |
$1,165 |
$6,799 |
$6.9 |
-$135 |
4.8 |
Sep-91 |
12.0 |
$5.00 |
$168 |
| Delivery Average |
|
63% |
-17% |
$772 |
$153 |
|
$757 |
$2.0 |
-$42 |
6.5 |
|
4.9 |
|
|
| Delivery Median |
|
70% |
-21% |
$256 |
$52 |
|
$207 |
$1.8 |
-$27 |
1.4 |
|
2.6 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
6/30/05 Close
|
% of 52wk High
|
% change since 6/30/04
|
Market Cap
($M)
|
Liquidity, Pro forma ($M)
|
ST< Debt ($M)
|
Company Valuation ($M)
|
Valuation/
Employee ($M)
|
Burn Rate, annualized ($M)
|
Survival Index (Yrs)
|
IPO Date
|
Cash/cash from IPO/share
|
Price/Share At IPO
|
IPO Post-Money Valuation ($M)
|
| ADVANCED MAGNETICS |
$11.16 |
46% |
-26% |
$90 |
$11 |
$0 |
$79 |
$3.6 |
-$10 |
1.1 |
na |
na |
na |
na |
| BIOSITE |
$54.99 |
81% |
22% |
$929 |
$109 |
$22 |
$841 |
$1.0 |
na |
na |
Feb-97 |
4.6 |
$12.00 |
$149 |
| CHOLESTECH CORP. |
$11.27 |
82% |
38% |
$165 |
$28 |
$0 |
$137 |
$0.7 |
na |
na |
Jun-92 |
2.3 |
$5.00 |
$32 |
| DIAGNOSTIC PRODUCTS CORP. |
$47.33 |
84% |
30% |
$1,387 |
$92 |
$3 |
$1,299 |
$0.6 |
na |
na |
Jun-82 |
11.8 |
$4.00 |
$43 |
| DIGENE CORP. |
$27.68 |
76% |
189% |
$554 |
$46 |
$1 |
$509 |
$1.7 |
na |
na |
May-96 |
2.4 |
$11.50 |
$128 |
| ENZO BIOCHEM |
$17.93 |
87% |
20% |
$576 |
$83 |
$0 |
$493 |
$2.3 |
na |
na |
Jun-80 |
20.6 |
$0.87 |
$8 |
| EPIX PHARMACEUTICALS |
$8.85 |
39% |
-58% |
$206 |
$154 |
$115 |
$167 |
$1.9 |
-$20 |
7.6 |
Feb-97 |
1.3 |
$7.00 |
$59 |
| EXACT SCIENCES CORP. |
$2.28 |
37% |
-63% |
$60 |
$42 |
$0 |
$18 |
$0.2 |
-$18 |
2.3 |
Jan-01 |
0.2 |
$14.00 |
$261 |
| GEN-PROBE |
$36.23 |
68% |
-23% |
$1,831 |
$241 |
$0 |
$1,590 |
$2.2 |
na |
na |
Sep-87 |
5.2 |
$7.00 |
$103 |
| IDEXX LABORATORIES |
$62.33 |
97% |
-1% |
$2,031 |
$132 |
$1 |
$1,900 |
$0.8 |
na |
na |
Jun-91 |
16.6 |
$3.75 |
$76 |
| IMMUCOR |
$28.95 |
80% |
100% |
$1,315 |
$24 |
$9 |
$1,300 |
$3.5 |
na |
na |
na |
na |
na |
na |
| IMMUNICON |
$5.08 |
48% |
-35% |
$118 |
$40 |
$6 |
$84 |
$0.8 |
-$33 |
1.2 |
Apr-04 |
0.6 |
$8.00 |
$186 |
| LUMINEX CORP. |
$9.84 |
96% |
-2% |
$308 |
$29 |
$0 |
$279 |
$2.1 |
-$5 |
6.0 |
Mar-00 |
0.6 |
$17.00 |
$450 |
| MARTEK BIOSCIENCES CORP. |
$37.96 |
54% |
-32% |
$1,202 |
$63 |
$70 |
$1,209 |
$3.1 |
na |
na |
Nov-93 |
5.4 |
$7.00 |
$54 |
| MATRITECH |
$0.70 |
48% |
-46% |
$31 |
$6 |
$1 |
$26 |
$0.4 |
-$10 |
0.6 |
Jul-92 |
0.1 |
$5.00 |
$22 |
| MERIDIAN BIOSCIENCE |
$18.95 |
88% |
71% |
$298 |
$6 |
$15 |
$308 |
$1.3 |
na |
na |
na |
na |
na |
na |
| ORASURE TECHNOLOGIES |
$9.98 |
99% |
3% |
$446 |
$68 |
$2 |
$380 |
$2.2 |
-$1 |
84.8 |
na |
na |
na |
na |
| QUIDEL CORP. |
$5.18 |
75% |
-12% |
$166 |
$46 |
$10 |
$129 |
$0.5 |
-$2 |
19.0 |
Aug-81 |
0.5 |
$10.00 |
$19 |
| SONUS PHARMACEUTICALS |
$3.51 |
74% |
-26% |
$75 |
$12 |
$0 |
$63 |
$1.5 |
-$14 |
0.8 |
Oct-95 |
0.5 |
$7.00 |
$60 |
| STRATAGENE |
$8.69 |
83% |
3% |
$192 |
$9 |
$6 |
$189 |
$1.3 |
na |
na |
na |
na |
na |
na |
| TRINITY BIOTECH PLC |
$6.50 |
48% |
93% |
$361 |
$26 |
$23 |
$358 |
$0.6 |
na |
na |
na |
na |
na |
na |
| XENOGEN |
$3.75 |
46% |
na |
$56 |
$12 |
$7 |
$51 |
$0.4 |
-$22 |
0.6 |
Jul-04 |
0.5 |
$7.00 |
$103 |
| Diagnostic/imag. Average |
|
70% |
12% |
$564 |
$58 |
|
$519 |
$1.5 |
-$14 |
12.4 |
|
4.6 |
|
|
| Diagnostic/imag. Median |
|
75% |
-1% |
$303 |
$41 |
|
$294 |
$1.3 |
-$12 |
1.7 |
|
1.8 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
6/30/05 Close
|
% of 52wk High
|
% change since 6/30/04
|
Market Cap
($M)
|
Liquidity, Pro forma ($M)
|
ST< Debt ($M)
|
Company Valuation ($M)
|
Valuation/
Employee ($M)
|
Burn Rate, annualized ($M)
|
Survival Index (Yrs)
|
IPO Date
|
Cash/cash from IPO/share
|
Price/Share At IPO
|
IPO Post-Money Valuation ($M)
|
| AASTROM BIOSCIENCES |
$3.12 |
72% |
247% |
$318 |
$33 |
$0 |
$284 |
$6.5 |
-$10 |
3.3 |
Feb-97 |
0.4 |
$7.00 |
$88 |
| AVIGEN |
$3.08 |
76% |
-9% |
$63 |
$57 |
$8 |
$14 |
$0.1 |
-$23 |
2.5 |
May-96 |
0.4 |
$8.00 |
$58 |
| CELL GENESYS |
$5.35 |
51% |
-49% |
$243 |
$165 |
$197 |
$274 |
$1.0 |
-$106 |
1.6 |
Jan-93 |
0.5 |
$11.00 |
$120 |
| CORAUTUS GENETICS |
$4.16 |
59% |
-28% |
$62 |
$20 |
$12 |
$54 |
$1.8 |
-$7 |
2.8 |
na |
na |
na |
na |
| GENVEC |
$1.84 |
59% |
-40% |
$102 |
$23 |
$4 |
$84 |
$1.0 |
-$19 |
1.2 |
Dec-00 |
0.2 |
$9.50 |
$186 |
| INTROGEN THERAPEUTICS |
$6.44 |
66% |
51% |
$199 |
$26 |
$9 |
$181 |
$2.5 |
-$28 |
0.9 |
Oct-00 |
0.8 |
$8.00 |
$167 |
| SIRNA THERAPEUTICS |
$1.75 |
45% |
-40% |
$73 |
$16 |
$0 |
$57 |
$0.8 |
-$36 |
0.5 |
Apr-96 |
0.2 |
$10.00 |
$59 |
| STEMCELLS |
$4.21 |
62% |
175% |
$263 |
$34 |
$2 |
$231 |
$8.3 |
-$17 |
2.0 |
Mar-92 |
0.4 |
$11.00 |
$82 |
| TARGETED GENETICS CORP. |
$0.81 |
41% |
-49% |
$69 |
$29 |
$11 |
$52 |
$0.6 |
-$9 |
3.2 |
May-94 |
0.1 |
$6.00 |
$54 |
| TRANSGENE SA |
$2.68 |
65% |
-11% |
$81 |
$15 |
$3 |
$69 |
$0.4 |
-$25 |
0.6 |
Mar-98 |
0.1 |
$43.50 |
$212 |
| TRANSKARYOTIC THERAPIES |
$36.58 |
99% |
145% |
$1,281 |
$131 |
$94 |
$1,244 |
$3.9 |
-$51 |
2.6 |
Oct-96 |
2.4 |
$15.00 |
$234 |
| VALENTIS |
$2.83 |
27% |
-59% |
$37 |
$10 |
$0 |
$28 |
$1.4 |
-$10 |
1.0 |
Sep-97 |
0.2 |
$12.00 |
$161 |
| VICAL |
$4.88 |
81% |
-16% |
$115 |
$58 |
$10 |
$67 |
$0.4 |
-$18 |
3.2 |
Mar-93 |
1.0 |
$5.00 |
$52 |
| Gene Therapy Average |
|
62% |
24% |
$224 |
$47 |
|
$203 |
$2.2 |
-$28 |
2.0 |
|
0.6 |
|
|
| Gene Therapy Median |
|
62% |
-16% |
$102 |
$29 |
|
$69 |
$1.0 |
-$23 |
2.0 |
|
0.4 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
6/30/05 Close
|
% of 52wk High
|
% change since 6/30/04
|
Market Cap
($M)
|
Liquidity, Pro forma ($M)
|
ST< Debt ($M)
|
Company Valuation ($M)
|
Valuation/
Employee ($M)
|
Burn Rate, annualized ($M)
|
Survival Index (Yrs)
|
IPO Date
|
Cash/cash from IPO/share
|
Price/Share At IPO
|
IPO Post-Money Valuation ($M)
|
| ADVANCIS |
$1.72 |
19% |
-74% |
$51 |
$17 |
$2 |
$36 |
$0.4 |
-$23 |
0.8 |
Oct-03 |
0.2 |
$10.00 |
$224 |
| ANADYS PHARMACEUTICALS |
$9.16 |
95% |
29% |
$205 |
$21 |
$2 |
$186 |
$2.3 |
-$30 |
0.7 |
Mar-04 |
1.3 |
$7.00 |
$157 |
| AVANT IMMUNOTHERAPEUTICS |
$1.17 |
42% |
-56% |
$87 |
$24 |
$0 |
$62 |
$1.1 |
-$15 |
1.6 |
May-86 |
0.3 |
$4.00 |
$38 |
| CUBIST PHARMACEUTICALS |
$13.17 |
97% |
19% |
$701 |
$88 |
$165 |
$778 |
$2.7 |
-$71 |
1.2 |
Oct-96 |
2.2 |
$6.00 |
$55 |
| DYNAVAX TECHNOLOGIES |
$4.80 |
55% |
-28% |
$119 |
$55 |
$0 |
$64 |
$1.5 |
-$21 |
2.6 |
Feb-04 |
0.6 |
$7.50 |
$186 |
| EPIMMUNE |
$0.72 |
36% |
-58% |
$12 |
$5 |
$0 |
$6 |
$0.2 |
-$4 |
1.4 |
Nov-91 |
0.0 |
$91.00 |
$167 |
| GENELABS TECHNOLOGIES |
$0.50 |
17% |
-78% |
$44 |
$21 |
$0 |
$24 |
$0.3 |
-$6 |
3.4 |
Jun-91 |
0.1 |
$9.13 |
$160 |
| IDENIX PHARMACEUTICALS |
$21.68 |
92% |
na |
$1,044 |
$107 |
$3 |
$939 |
$6.6 |
-$56 |
1.9 |
Jul-04 |
1.5 |
$14.00 |
$684 |
| IMMUNE RESPONSE CORP. |
$0.65 |
37% |
-47% |
$32 |
$1 |
$7 |
$38 |
$0.8 |
-$17 |
0.1 |
May-90 |
0.0 |
$28.00 |
$77 |
| INHIBITEX |
$7.56 |
59% |
5% |
$190 |
$73 |
$3 |
$120 |
$2.0 |
-$24 |
3.0 |
Jun-04 |
1.1 |
$7.00 |
$176 |
| INTERMUNE |
$13.04 |
85% |
-15% |
$425 |
$154 |
$170 |
$441 |
$1.7 |
-$87 |
1.8 |
Mar-00 |
0.7 |
$20.00 |
$433 |
| NABI BIOPHARMACEUTICALS |
$15.23 |
97% |
7% |
$896 |
$67 |
$15 |
$843 |
$1.2 |
-$68 |
1.0 |
na |
na |
na |
na |
| SIGA TECHNOLOGIES |
$1.08 |
60% |
-23% |
$26 |
($1) |
$0 |
$27 |
$1.6 |
-$7 |
(0.1) |
Sep-97 |
0.2 |
$5.00 |
$32 |
| TRIMERIS |
$9.98 |
62% |
-31% |
$219 |
$44 |
$0 |
$175 |
$1.8 |
-$23 |
1.9 |
Oct-97 |
0.8 |
$12.00 |
$120 |
| VAXGEN |
$10.85 |
54% |
-23% |
$272 |
$10 |
$2 |
na |
na |
na |
na |
Jul-99 |
0.8 |
$13.00 |
$146 |
| VICURON PHARMACEUTICALS |
$27.90 |
99% |
122% |
$1,698 |
$125 |
$11 |
$1,584 |
$42.8 |
-$62 |
2.0 |
Sep-00 |
2.5 |
$11.00 |
$249 |
| VION PHARMACEUTICALS |
$2.17 |
42% |
-48% |
$143 |
$64 |
$0 |
$79 |
$2.7 |
-$16 |
4.1 |
Aug-95 |
0.5 |
$4.00 |
$32 |
| VIROLOGIC |
$2.48 |
84% |
1% |
$302 |
$75 |
$1 |
$227 |
$1.2 |
-$6 |
11.8 |
May-00 |
0.4 |
$7.00 |
$137 |
| VIROPHARMA |
$6.95 |
94% |
288% |
$196 |
$54 |
$180 |
$321 |
$3.6 |
-$13 |
4.1 |
Nov-96 |
1.0 |
$7.00 |
$65 |
| XOMA LTD |
$1.68 |
36% |
-63% |
$145 |
$44 |
$60 |
$162 |
$0.7 |
-$80 |
0.5 |
Jun-86 |
0.1 |
$16.00 |
$140 |
| Infection Average |
|
63% |
-4% |
$340 |
$53 |
|
$322 |
$4.0 |
-$33 |
2.3 |
|
0.8 |
|
|
| Infection Median |
|
60% |
-23% |
$193 |
$49 |
|
$162 |
$1.6 |
-$23 |
1.8 |
|
0.6 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
6/30/05 Close
|
% of 52wk High
|
% change since 6/30/04
|
Market Cap
($M)
|
Liquidity, Pro forma ($M)
|
ST< Debt ($M)
|
Company Valuation ($M)
|
Valuation/
Employee ($M)
|
Burn Rate, annualized ($M)
|
Survival Index (Yrs)
|
IPO Date
|
Cash/cash from IPO/share
|
Price/Share At IPO
|
IPO Post-Money Valuation ($M)
|
| AMYLIN PHARMACEUTICALS |
$20.93 |
84% |
-8% |
$2,182 |
$406 |
$375 |
$2,151 |
$9.6 |
-$186 |
2.2 |
Jan-92 |
1.5 |
$14.00 |
$240 |
| BIOMARIN PHARMACEUTICAL |
$7.48 |
96% |
25% |
$484 |
($33) |
$149 |
$665 |
$2.4 |
-$330 |
(0.1) |
Aug-99 |
0.6 |
$13.00 |
$449 |
| INSMED |
$0.98 |
40% |
-56% |
$44 |
$29 |
$21 |
$37 |
$1.8 |
-$30 |
0.9 |
na |
na |
na |
na |
| KERYX BIOPHARMACEUTICALS |
$13.20 |
84% |
4% |
$416 |
$35 |
$0 |
$381 |
$15.9 |
-$13 |
2.7 |
Jul-00 |
1.3 |
$10.00 |
$194 |
| MANNKIND |
$10.05 |
41% |
na |
$329 |
$50 |
$0 |
$280 |
$1.3 |
-$85 |
0.6 |
Jul-04 |
0.7 |
$14.00 |
$446 |
| METABASIS THERAPEUTICS |
$3.15 |
39% |
-55% |
$57 |
$34 |
$2 |
$25 |
$0.3 |
-$20 |
1.7 |
Jun-04 |
0.5 |
$7.00 |
$127 |
| NPS PHARMACEUTICALS |
$11.35 |
48% |
-46% |
$440 |
$245 |
$367 |
$562 |
$2.1 |
-$208 |
1.2 |
May-94 |
2.1 |
$5.50 |
$40 |
| SAVIENT PHARMACEUTICALS |
$4.41 |
98% |
78% |
$268 |
$105 |
$4 |
$167 |
$0.4 |
na |
na |
Sep-83 |
0.3 |
$13.00 |
$68 |
| TERCICA |
$8.69 |
77% |
6% |
$274 |
$82 |
$0 |
$192 |
$4.7 |
-$43 |
1.9 |
Mar-04 |
1.0 |
$9.00 |
$284 |
| VIVUS |
$3.69 |
58% |
1% |
$164 |
$48 |
$4 |
$120 |
$1.0 |
-$4 |
13.2 |
Apr-94 |
0.5 |
$7.00 |
$164 |
| ZONAGEN |
$3.83 |
64% |
50% |
$39 |
$22 |
$0 |
$17 |
$4.2 |
-$6 |
3.9 |
Mar-93 |
0.7 |
$5.50 |
$19 |
| Metabolic Average |
|
66% |
0% |
$427 |
$93 |
|
$418 |
$4.0 |
-$92 |
2.8 |
|
0.9 |
|
|
| Metabolic Median |
|
64% |
3% |
$274 |
$48 |
|
$192 |
$2.1 |
-$37 |
1.8 |
|
0.7 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
6/30/05 Close
|
% of 52wk High
|
% change since 6/30/04
|
Market Cap
($M)
|
Liquidity, Pro forma ($M)
|
ST< Debt ($M)
|
Company Valuation ($M)
|
Valuation/
Employee ($M)
|
Burn Rate, annualized ($M)
|
Survival Index (Yrs)
|
IPO Date
|
Cash/cash from IPO/share
|
Price/Share At IPO
|
IPO Post-Money Valuation ($M)
|
| ALNYLAM PHARMACEUTICALS |
$7.30 |
66% |
-3% |
$153 |
$34 |
$8 |
$127 |
$2.1 |
-$23 |
1.5 |
May-04 |
1.2 |
$6.00 |
$126 |
| AUXILIUM PHARMACEUTICALS |
$4.77 |
47% |
na |
$99 |
$35 |
$1 |
$64 |
$0.5 |
-$28 |
1.3 |
Jul-04 |
0.6 |
$7.50 |
$160 |
| BARRIER THERAPEUTICS |
$7.93 |
35% |
-43% |
$190 |
$99 |
$1 |
$92 |
$2.2 |
-$53 |
1.9 |
Apr-04 |
0.5 |
$15.00 |
$360 |
| CRITICAL THERAPEUTICS |
$7.02 |
83% |
0% |
$169 |
$58 |
$2 |
$113 |
$1.1 |
-$45 |
1.3 |
May-04 |
1.0 |
$7.00 |
$169 |
| EYETECH PHARMACEUTICALS |
$12.64 |
26% |
-71% |
$546 |
$244 |
$2 |
$305 |
$1.9 |
-$119 |
2.0 |
Jan-04 |
0.6 |
$21.00 |
$907 |
| MOMENTA PHARMACEUTICALS |
$19.77 |
89% |
123% |
$504 |
$47 |
$2 |
$458 |
$12.7 |
-$17 |
2.8 |
Jun-04 |
3.0 |
$6.50 |
$166 |
| SANTARUS |
$4.10 |
27% |
-72% |
$149 |
$76 |
$0 |
$73 |
$1.0 |
-$85 |
0.9 |
Mar-04 |
0.5 |
$9.00 |
$328 |
| Other Average |
|
54% |
-11% |
$259 |
$85 |
|
$176 |
$3.1 |
-$53 |
1.7 |
|
1.1 |
|
|
| Other Median |
|
47% |
-23% |
$169 |
$58 |
|
$113 |
$1.9 |
-$45 |
1.5 |
|
0.6 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
6/30/05 Close
|
% of 52wk High
|
% change since 6/30/04
|
Market Cap
($M)
|
Liquidity, Pro forma ($M)
|
ST< Debt ($M)
|
Company Valuation ($M)
|
Valuation/
Employee ($M)
|
Burn Rate, annualized ($M)
|
Survival Index (Yrs)
|
IPO Date
|
Cash/cash from IPO/share
|
Price/Share At IPO
|
IPO Post-Money Valuation ($M)
|
| AMGEN |
$60.46 |
93% |
11% |
$74,970 |
$4,908 |
$3,942 |
$74,004 |
$5.7 |
na |
na |
Jun-83 |
172.7 |
$0.35 |
$175 |
| BIOGEN IDEC |
$34.45 |
49% |
-46% |
$11,873 |
$1,334 |
$846 |
$11,384 |
$3.1 |
na |
na |
Sep-91 |
13.8 |
$2.50 |
$131 |
| CHIRON CORP. |
$34.89 |
73% |
-22% |
$6,540 |
$797 |
$1,096 |
$6,840 |
$1.3 |
na |
na |
Aug-83 |
11.6 |
$3.00 |
$98 |
| GENENTECH |
$80.28 |
95% |
43% |
$85,097 |
$2,117 |
$456 |
$83,436 |
$13.4 |
na |
na |
Oct-80 |
55.4 |
$1.45 |
$246 |
| GENZYME CORP. |
$60.09 |
92% |
27% |
$15,160 |
$726 |
$840 |
$15,274 |
$2.7 |
na |
na |
Jun-86 |
24.0 |
$2.50 |
$70 |
| GILEAD SCIENCES |
$43.99 |
95% |
31% |
$19,875 |
$1,549 |
$1 |
$18,326 |
$12.9 |
na |
na |
Jan-92 |
11.7 |
$3.75 |
$210 |
| MEDIMMUNE |
$26.72 |
93% |
14% |
$6,620 |
$635 |
$506 |
$6,491 |
$3.9 |
na |
na |
May-91 |
17.4 |
$1.54 |
$114 |
| Revenue-driven Average |
|
84% |
8% |
$31,448 |
$1,724 |
|
$30,822 |
$6.1 |
na |
na |
|
43.8 |
|
|
| Revenue-driven Median |
|
93% |
14% |
$15,160 |
$1,334 |
|
$15,274 |
$3.9 |
na |
na |
|
17.4 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
6/30/05 Close
|
% of 52wk High
|
% change since 6/30/04
|
Market Cap
($M)
|
Liquidity, Pro forma ($M)
|
ST< Debt ($M)
|
Company Valuation ($M)
|
Valuation/
Employee ($M)
|
Burn Rate, annualized ($M)
|
Survival Index (Yrs)
|
IPO Date
|
Cash/cash from IPO/share
|
Price/Share At IPO
|
IPO Post-Money Valuation ($M)
|
| DIVERSA CORP. |
$5.21 |
51% |
-49% |
$229 |
$83 |
$17 |
$163 |
$0.5 |
-$24 |
3.4 |
Feb-00 |
0.2 |
$24.00 |
$840 |
| DYAX CORP. |
$4.71 |
39% |
-60% |
$149 |
$43 |
$13 |
$119 |
$1.1 |
-$38 |
1.1 |
Aug-00 |
0.3 |
$15.00 |
$295 |
| ISIS PHARMACEUTICALS |
$3.91 |
59% |
-32% |
$225 |
$34 |
$253 |
$444 |
$1.0 |
-$230 |
0.1 |
May-91 |
0.4 |
$10.00 |
$104 |
| LIGAND PHARMACEUTICALS |
$6.96 |
43% |
-60% |
$515 |
$77 |
$174 |
$612 |
$1.3 |
-$27 |
2.8 |
Nov-92 |
0.8 |
$8.27 |
$131 |
| NEUROGEN CORP. |
$6.82 |
65% |
-9% |
$235 |
$140 |
$13 |
$108 |
$0.7 |
-$12 |
12.1 |
Oct-89 |
1.1 |
$6.00 |
$35 |
| REGENERON PHARMACEUTICALS |
$8.39 |
78% |
-20% |
$471 |
$356 |
$200 |
$314 |
$4.9 |
na |
na |
Apr-91 |
0.4 |
$22.00 |
$330 |
| SENOMYX |
$16.51 |
98% |
164% |
$420 |
$32 |
$0 |
$388 |
$5.3 |
-$24 |
1.3 |
Jun-04 |
2.8 |
$6.00 |
$153 |
| Screening Average |
|
62% |
-9% |
$321 |
$109 |
|
$307 |
$2.1 |
-$59 |
3.5 |
|
0.9 |
|
|
| Screening Median |
|
59% |
-32% |
$235 |
$77 |
|
$314 |
$1.1 |
-$26 |
2.1 |
|
0.4 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
6/30/05 Close
|
% of 52wk High
|
% change since 6/30/04
|
Market Cap
($M)
|
Liquidity, Pro forma ($M)
|
ST< Debt ($M)
|
Company Valuation ($M)
|
Valuation/
Employee ($M)
|
Burn Rate, annualized ($M)
|
Survival Index (Yrs)
|
IPO Date
|
Cash/cash from IPO/share
|
Price/Share At IPO
|
IPO Post-Money Valuation ($M)
|
| CARRINGTON LABORATORIES |
$4.50 |
61% |
1% |
$48 |
$3 |
$4 |
$49 |
$0.2 |
na |
na |
na |
na |
na |
na |
| CELLEGY PHARMACEUTICALS |
$1.63 |
30% |
-58% |
$43 |
$2 |
$5 |
$46 |
$2.3 |
-$12 |
0.2 |
Aug-95 |
0.3 |
$6.25 |
$24 |
| CURATIVE HEALTH SERVICES |
$2.28 |
25% |
-74% |
$30 |
$5 |
$6 |
$31 |
$0.1 |
-$28 |
0.2 |
Jun-91 |
0.3 |
$7.50 |
$74 |
| LIFECELL CORP. |
$15.81 |
96% |
41% |
$463 |
$33 |
$0 |
$430 |
$2.5 |
na |
na |
Feb-92 |
2.0 |
$7.75 |
$27 |
| LIFECORE BIOMEDICAL |
$10.91 |
58% |
78% |
$142 |
$16 |
$0 |
$127 |
$0.6 |
na |
na |
na |
na |
na |
na |
| Wound Average |
|
54% |
-2% |
$145 |
$12 |
|
$136 |
$1.1 |
-$20 |
0.2 |
|
0.9 |
|
|
| Wound Median |
|
58% |
1% |
$48 |
$5 |
|
$49 |
$0.6 |
-$20 |
0.2 |
|
0.3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Overall Average |
|
62% |
-11% |
$1,387 |
$152 |
|
$1,338 |
$2.7 |
-$49 |
3.3 |
|
3.0 |
|
|
| Overall Median |
|
64% |
-20% |
$243 |
$58 |
|
$190 |
$1.6 |
-$28 |
1.8 |
|
0.7 |
|
|
originally published 07/08/2005 |